Liver cirrhosis and decompensation still on the rise among people with hepatitis C
Is DAA treatment for hepatitis C reducing the need for liver transplants?
Liver cancer risk reduced after hepatitis C treatment, but vigilance needed for aggressive cancers in months after treatment
Statins reduce risk of progression to cirrhosis in people with HIV/HCV co-infection
HIV not a risk factor for fibrosis progression in people with hepatitis C
Incidence of liver cancer is increasing in people with HIV/HCV co-infection
Only treating patients with cirrhosis with DAAs will have limited impact on HCV epidemic in England
People treated for hepatitis C have unexpectedly high rate of liver cancer recurrence
Hepatitis C treatment may not be enough to stop the progress of advanced liver disease, or reduce liver transplant need
